EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy

Area of Science:

• Oncology
• Translational Research
• Pharmacology

Background:

• Advanced non-small-cell lung cancer (NSCLC) with EGFR mutations exemplifies oncogene addiction.
• EGFR tyrosine kinase inhibitors (TKIs) are primary treatments, with ongoing research into resistance mechanisms and optimal sequencing.
• Translational research focuses on defining the best initial and subsequent therapeutic strategies.

Purpose of the Study:

• To review current first-line therapies for treatment-naïve EGFR-mutated advanced NSCLC.
• To recommend optimal therapeutic strategies based on clinical and biological parameters.

Main Methods:

• Review of large randomized phase 3 trials evaluating EGFR TKIs alone or in combination with anti-angiogenic drugs or chemotherapy.
• Analysis of factors influencing treatment selection, including patient characteristics and mutation type.

Main Results:

• EGFR TKIs, in various combinations, improve progression-free survival (PFS) and overall survival (OS) in EGFR-mutated NSCLC.
• Osimertinib is identified as a preferred first-line option in 2020.
• Treatment choice requires balancing efficacy with patient factors and mutation specifics.

Conclusions:

• Osimertinib is the current first-line standard for EGFR-mutated NSCLC.
• Personalized treatment selection is crucial, integrating patient characteristics, EGFR mutation status, and evolving therapeutic options.